Innate Pharma SA

IPHA Nasdaq CIK: 0001598599

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Accelerated filer
State of Incorporation France
Country France
Business Address 117 AVENUE DE LUMINY, MARSEILLE, , 13009
Mailing Address 117 AVENUE DE LUMINY, MARSEILLE, , 13009
Phone 33430303030
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024

Recent SEC Filings

Form Type Date Filed Document
20-F Foreign company annual report April 1, 2026 View on SEC
6-K Foreign company current report March 26, 2026 View on SEC
6-K Foreign company current report March 19, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 4, 2026 View on SEC
6-K Foreign company current report February 18, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 6, 2026 View on SEC
6-K Foreign company current report January 7, 2026 View on SEC
6-K Foreign company current report December 22, 2025 View on SEC
6-K Foreign company current report December 11, 2025 View on SEC
6-K Foreign company current report November 28, 2025 View on SEC

Annual Reports

20-F April 1, 2026
  • Strategic partnership model with industry giants like AstraZeneca, Sanofi, and Takeda reduces late-stage clinical trial costs.
  • Focus on innovative immuno-oncology and NK cell technology provides a specialized niche in the biotech sector.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.